Substance / Medication

Yohimbine

Overview

Active Ingredient
yohimbine
RxNorm CUI
220982

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

78 trials linked to this intervention

78
Total Trials
2
Recruiting
14
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Yohimbine as a pharmacological probe for alcohol research: a systematic review of rodent and human studies.
Curley Dallece E, Vasaturo-Kolodner Talia R, Cannella Nazzareno et al. · Neuropsychopharmacology · 2022
PMID: 35760866Meta-AnalysisFull text (PMC)
The effects of yohimbine and hydrocortisone on selective attention to fearful faces: An fMRI study.
Metz Sophie, Mengering Leon, Lipka Renée et al. · Psychoneuroendocrinology · 2024
PMID: 38581746RCT
The effects of hydrocortisone and yohimbine on human behavior in approach-avoidance conflicts.
Fricke Kim, Alexander Nina, Jacobsen Thomas et al. · Psychopharmacology (Berl) · 2023
PMID: 37314480RCTFull text (PMC)
Effects of Acute Yohimbine Hydrochloride Supplementation on Repeated Supramaximal Sprint Performance.
Barnes Megan E, Cowan Camryn R, Boag Lauren E et al. · Int J Environ Res Public Health · 2022
PMID: 35162339RCTFull text (PMC)
Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear.
Sperl Matthias F J, Panitz Christian, Skoluda Nadine et al. · Int J Neuropsychopharmacol · 2022
PMID: 35748393RCTFull text (PMC)
Effects of hydrocortisone and yohimbine on selective attention to emotional cues.
Metz Sophie, Chae Woo R, Deuter Christian E et al. · J Psychopharmacol · 2021
PMID: 33779376RCTFull text (PMC)
Effects of hydrocortisone and yohimbine on decision-making under risk.
Metz Sophie, Waiblinger-Grigull Tina, Schulreich Stefan et al. · Psychoneuroendocrinology · 2020
PMID: 32028083RCT
Impact of endogenous progesterone on reactivity to yohimbine and cocaine cues in cocaine-dependent women.
Moran-Santa Maria Megan M, Sherman Brian J, Brady Kathleen T et al. · Pharmacol Biochem Behav · 2018
PMID: 29126857RCTFull text (PMC)
Augmenting treatment efficiency in exposure therapy for PTSD: a randomized double-blind placebo-controlled trial of yohimbine HCl.
Tuerk Peter W, Wangelin Bethany C, Powers Mark B et al. · Cogn Behav Ther · 2018
PMID: 29448886RCT
Comparison of Atipamezole with Yohimbine for Antagonism of Xylazine in Mice Anesthetized with Ketamine and Xylazine.
Janssen Christopher F, Maiello Pauline, Wright M Jerry et al. · J Am Assoc Lab Anim Sci · 2017
PMID: 28315642RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Yohimbine (substance)
SNOMED CT
73407000
UMLS CUI
C0724441
RxNorm CUI
220982

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
78
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.